Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Free Cash Flow: 2013-2024

Historic Free Cash Flow for Collegium Pharmaceutical (COLL) over the last 12 years, with Dec 2024 value amounting to $203.3 million.

  • Collegium Pharmaceutical's Free Cash Flow rose 946.59% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $289.3 million, marking a year-over-year increase of 50.34%. This contributed to the annual value of $203.3 million for FY2024, which is 25.87% down from last year.
  • Collegium Pharmaceutical's Free Cash Flow amounted to $203.3 million in FY2024, which was down 25.87% from $274.3 million recorded in FY2023.
  • Collegium Pharmaceutical's 5-year Free Cash Flow high stood at $274.3 million for FY2023, and its period low was $88.4 million during FY2020.
  • Over the past 3 years, Collegium Pharmaceutical's median Free Cash Flow value was $203.3 million (recorded in 2024), while the average stood at $200.1 million.
  • In the last 5 years, Collegium Pharmaceutical's Free Cash Flow skyrocketed by 314.13% in 2020 and then decreased by 25.87% in 2024.
  • MRY analysis of 5 years shows Collegium Pharmaceutical's Free Cash Flow stood at $88.4 million in 2020, then rose by 14.95% to $101.6 million in 2021, then grew by 20.66% to $122.6 million in 2022, then soared by 123.71% to $274.3 million in 2023, then decreased by 25.87% to $203.3 million in 2024.
  • Its Free Cash Flow stands at $203.3 million for FY2024, versus $274.3 million for FY2023 and $122.6 million for FY2022.